Sign In
Buy PHR
$9.15
+0.230 (+2.58%)
At Close: Jun 23, 2026
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
06:16pm, Wednesday, 12'th Mar 2025
Phreesia (PHR) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.56 per share a year ago.
Phreesia Announces Fourth Quarter Fiscal 2025 Results
04:03pm, Wednesday, 12'th Mar 2025
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended
Phreesia (PHR) Moves 5.6% Higher: Will This Strength Last?
08:06am, Friday, 14'th Feb 2025
Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
Phreesia's Sally Thayer Selected as a Top Woman Leader in Software
06:48am, Tuesday, 11'th Feb 2025
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia announced that Sally Thayer, VP of Product Management, is a winner for The Software Report's 2024 list of Top 50 Women Leaders in Softwar
Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2025 Results
04:15pm, Friday, 07'th Feb 2025
ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia will release its fiscal fourth quarter and fiscal year 2025 financial results after the close of market trading on Wednesday, March 12.
Phreesia, Inc. (PHR) Soars to 52-Week High, Time to Cash Out?
10:16am, Wednesday, 29'th Jan 2025
Phreesia (PHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Enovis, Omnicell and Phreesia
02:51am, Friday, 24'th Jan 2025
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects
12:21pm, Thursday, 23'rd Jan 2025
Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave.
Phreesia (PHR) Upgraded to Buy: Here's Why
01:00pm, Tuesday, 14'th Jan 2025
Phreesia (PHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Buy Phreesia (PHR) After Golden Cross?
11:06am, Wednesday, 08'th Jan 2025
From a technical perspective, Phreesia, Inc. (PHR) is looking like an interesting pick, as it just reached a key level of support. PHR's 50-day simple moving average crossed above its 200-day simple m
Wall Street Analysts See a 25% Upside in Phreesia (PHR): Can the Stock Really Move This High?
10:56am, Friday, 20'th Dec 2024
The consensus price target hints at a 25% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re
Phreesia Has Turned The Corner, Can It Continue To Mend?
06:44am, Thursday, 12'th Dec 2024
Phreesia's Q3 earnings show solid revenue growth, but customer growth is decelerating, impacting overall performance. Fiscal 2025 guidance improved with higher EBITDA and tighter revenue estimates, wh
Phreesia, Inc. (PHR) Q3 2025 Earnings Call Transcript
07:22pm, Monday, 09'th Dec 2024
Phreesia, Inc. (PHR) Q3 2025 Earnings Call Transcript
Phreesia (PHR) Reports Q3 Earnings: What Key Metrics Have to Say
07:00pm, Monday, 09'th Dec 2024
While the top- and bottom-line numbers for Phreesia (PHR) give a sense of how the business performed in the quarter ended October 2024, it could be worth looking at how some of its key metrics compare
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
06:20pm, Monday, 09'th Dec 2024
Phreesia (PHR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.58 per share a year ago.
